Genomtec raises €2.6M to commercialise diagnostics and accelerate AI-based assay development

What's the deal? Genomtec, a Polish diagnostics developer, has secured €2.6M ($3M) in equity financing to commercialise its diagnostics platforms and accelerate AI-based molecular test development.

The funding will support two priorities: bringing the company's existing diagnostics products to market and building AI tools designed to streamline the creation of new molecular assays.

The signal: Genomtec sits at the intersection of two high-demand sectors — molecular diagnostics and AI-driven drug and test development — yet remains at the early growth stage, according to Dealroom. The modest size of the round suggests the company is still proving out its commercial model, but the dual focus on product rollout and AI-powered assay design positions it to scale faster if its platform delivers on the promise of cheaper, quicker test creation.